Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Portfolio Pulse from Vandana Singh
Blood tests for diagnosing Alzheimer's disease are in development but not yet approved by regulators or insurance reimbursement. Eisai Co Ltd's and Biogen Inc's new Alzheimer's drug, Leqembi, currently relies on cognitive assessments or invasive cerebrospinal fluid tests. Laboratory Corporation Of America Holdings and Quest Diagnostics Incorporated have introduced blood tests measuring amyloid, tau, and neurodegeneration. Eli Lilly And Co is working with Quanterix on an experimental tau biomarker blood test and has partnered with Roche Holdings AG to develop a test measuring blood levels of a different tau protein and a gene associated with Alzheimer's risk.
October 11, 2023 | 6:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen Inc's new Alzheimer's drug, Leqembi, currently relies on cognitive assessments or invasive cerebrospinal fluid tests.
The development of blood tests for Alzheimer's could potentially impact the use of Biogen's drug, Leqembi, which currently relies on more invasive tests.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Eisai Co Ltd's new Alzheimer's drug, Leqembi, currently relies on cognitive assessments or invasive cerebrospinal fluid tests.
The development of blood tests for Alzheimer's could potentially impact the use of Eisai's drug, Leqembi, which currently relies on more invasive tests.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Quest Diagnostics Incorporated has introduced blood tests measuring amyloid, tau, and neurodegeneration.
The introduction of these blood tests by Quest Diagnostics could potentially increase their revenues if these tests are approved and widely adopted.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Laboratory Corporation Of America Holdings has introduced blood tests measuring amyloid, tau, and neurodegeneration.
The introduction of these blood tests by LabCorp could potentially increase their revenues if these tests are approved and widely adopted.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Eli Lilly And Co is working with Quanterix on an experimental tau biomarker blood test and has partnered with Roche Holdings AG to develop a test measuring blood levels of a different tau protein and a gene associated with Alzheimer's risk.
Eli Lilly's involvement in the development of these blood tests could potentially increase their revenues if these tests are approved and widely adopted.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Roche Holdings AG is partnering with Eli Lilly And Co to develop a test measuring blood levels of a different tau protein and a gene associated with Alzheimer's risk.
Roche's involvement in the development of these blood tests could potentially increase their revenues if these tests are approved and widely adopted.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90